Hematopoietic Progenitor Kinase 1 in Tumor Immunology: A Medicinal Chemistry Perspective

J Med Chem. 2022 Jun 23;65(12):8065-8090. doi: 10.1021/acs.jmedchem.2c00172. Epub 2022 Jun 13.

Abstract

Hematopoietic progenitor kinase 1 (HPK1), a hematopoietic cell-restricted member of the serine/threonine Ste20-related protein kinases, is a negative regulator of the T cell receptor, B cell receptor, and dendritic cells. Loss of HPK1 kinase function increases cytokine secretion and enhances T cell signaling, virus clearance, and tumor growth inhibition. Therefore, HPK1 is considered a promising target for tumor immunotherapy. Several HPK1 inhibitors have been reported to regulate T cell function. In addition, HPK1-targeting PROTACs, which can induce the degradation of HPK1, have also been developed. Here, we provide an overview of research concerning HPK1 protein structure, function, and inhibitors and propose perspectives and insights for the future development of agents targeting HPK1.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chemistry, Pharmaceutical*
  • Humans
  • Neoplasms* / drug therapy
  • Protein Serine-Threonine Kinases
  • Signal Transduction

Substances

  • hematopoietic progenitor kinase 1
  • Protein Serine-Threonine Kinases